Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935078 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL29223244 | 0.98 | CXCR4 (0.52) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL24177173 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL934649 | 0.96 | CXCR4 (0.55) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL5134779 | 0.96 | CXCR4 (0.55) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL13805257 | 0.96 | SIGMAR1 (0.48) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL8675042 | 0.94 | CHRM5 (0.49) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL8507105 | 0.94 | HSD17B10 (0.47) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| Pyrrolidine SCHEMBL4661508 | 0.94 | CHRM5 (0.52) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 | |
| SCHEMBL28997961 | 0.92 | CHRM5 (0.47) | SIGMAR1CHRM5CHRM3CXCR4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005027713-A2 | COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005017102-A2 | COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO OVARIAN SPECIFIC NUCLEIC ACIDS AND PROTEINS | DIADEXUS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004092338-A2 | COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO CANCER SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004013311-A2 | COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003060121-A2 | COMPOSITIONS AND METHODS RELATING TO GASTRIC SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060069-A2 | COMPOSITIONS AND METHODS RELATING TO HEPATIC SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003055982-A2 | COMPOSITIONS AND METHODS RELATING TO ENDOMETRIAL SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003020953-A2 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020934-A1 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002092785-A2 | COMPOSITION AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002064744-A2 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002055735-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | SIGMAR1 1082/4885CHRM5 4512/4885CHRM3 3715/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | SIGMAR1 3899/4885CHRM5 4763/4885CHRM3 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.